Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBIT Margin for 4 consecutive years, with 67.95% as the latest value for Q1 2025.

  • Quarterly EBIT Margin rose 372982.0% to 67.95% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1.85% through Dec 2025, up 209431.0% year-over-year, with the annual reading at 1.86% for FY2025, 209462.0% up from the prior year.
  • EBIT Margin for Q1 2025 was 67.95% at Century Therapeutics, up from 893.46% in the prior quarter.
  • The five-year high for EBIT Margin was 67.95% in Q1 2025, with the low at 35431.31% in Q2 2023.
  • Average EBIT Margin over 4 years is 8053.42%, with a median of 3661.87% recorded in 2024.
  • The sharpest move saw EBIT Margin plummeted -3318554bps in 2023, then skyrocketed 3092353bps in 2024.
  • Over 4 years, EBIT Margin stood at 6392.71% in 2022, then plummeted by -155bps to 16329.1% in 2023, then surged by 95bps to 893.46% in 2024, then skyrocketed by 108bps to 67.95% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 67.95%, 893.46%, and 4398.1% for Q1 2025, Q4 2024, and Q3 2024 respectively.